Avastin approved for lung cancer in Japan
This article was originally published in Scrip
Chugai/Roche's VEGF-targeting antibody Avastin (bevacizumab) has been formally approved in Japan for the first-line treatment of unresectable advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context